TW202241886A - 雌激素受體調節劑 - Google Patents

雌激素受體調節劑 Download PDF

Info

Publication number
TW202241886A
TW202241886A TW110148064A TW110148064A TW202241886A TW 202241886 A TW202241886 A TW 202241886A TW 110148064 A TW110148064 A TW 110148064A TW 110148064 A TW110148064 A TW 110148064A TW 202241886 A TW202241886 A TW 202241886A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
mmol
acceptable salt
compound according
compound
Prior art date
Application number
TW110148064A
Other languages
English (en)
Chinese (zh)
Inventor
國寶 張
琴華 黃
凱文 杜安 班納
薩伊 葛迦納 赫格德
Original Assignee
美商瑞卡瑞恩Ｉｐ控股有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑞卡瑞恩Ｉｐ控股有限責任公司 filed Critical 美商瑞卡瑞恩Ｉｐ控股有限責任公司
Publication of TW202241886A publication Critical patent/TW202241886A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110148064A 2020-12-23 2021-12-22 雌激素受體調節劑 TW202241886A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063130123P 2020-12-23 2020-12-23
US63/130,123 2020-12-23
US202163164095P 2021-03-22 2021-03-22
US63/164,095 2021-03-22
US202163265052P 2021-12-07 2021-12-07
US63/265,052 2021-12-07

Publications (1)

Publication Number Publication Date
TW202241886A true TW202241886A (zh) 2022-11-01

Family

ID=81656364

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110148064A TW202241886A (zh) 2020-12-23 2021-12-22 雌激素受體調節劑

Country Status (5)

Country Link
US (2) US11339162B1 (https=)
EP (1) EP4267578A4 (https=)
JP (1) JP2024502270A (https=)
TW (1) TW202241886A (https=)
WO (1) WO2022140744A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4267578A4 (en) * 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
TW202317539A (zh) * 2021-07-15 2023-05-01 大陸商四川海思科製藥有限公司 芳氨基衍生物雌激素受體調節劑及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
JP2005508968A (ja) 2001-10-19 2005-04-07 トランス　テック　ファーマ，インコーポレイテッド ＰＴＰ阻害剤としてのβ−カルボリン誘導体
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
EP1829874B1 (en) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011150162A1 (en) 2010-05-27 2011-12-01 Ptc Therapeutics, Inc. Methods for treating viral conditions
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9499538B2 (en) 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
MX388871B (es) 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
WO2016069949A1 (en) 2014-10-29 2016-05-06 Virginia Tech Intellectual Properties, Inc. Compositions and formulations of methylerthritol phosphate pathway inhibitors and uses thereof
TWI874834B (zh) * 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
EP3472162B1 (en) 2016-06-16 2021-11-17 F. Hoffmann-La Roche AG Heteroaryl estrogen receptor modulators and uses thereof
WO2018130123A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN109867659A (zh) 2017-12-04 2019-06-11 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物的制备方法
CN111601797B (zh) 2018-05-23 2022-11-22 江苏恒瑞医药股份有限公司 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
CR20200621A (es) * 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
JP7571006B2 (ja) 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
AU2020380211A1 (en) 2019-11-04 2022-05-19 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
WO2021216671A1 (en) 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader
EP4267578A4 (en) * 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS

Also Published As

Publication number Publication date
US11999728B2 (en) 2024-06-04
US20220235050A1 (en) 2022-07-28
US11339162B1 (en) 2022-05-24
JP2024502270A (ja) 2024-01-18
EP4267578A1 (en) 2023-11-01
WO2022140744A1 (en) 2022-06-30
EP4267578A4 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
AU2020294196B2 (en) Estrogen receptor modulators
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
KR102737181B1 (ko) Jak 억제제 및 그 제조방법과 의약분야에서의 응용
KR102659741B1 (ko) 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도
CN109867676B (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
JP2021516242A (ja) 置換１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン
KR20220034805A (ko) Bcl-2 단백질 억제제
CA3105681A1 (en) Pyridazinone derivative
EA011161B1 (ru) 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве h-лигандов
KR20180003614A (ko) 바이사이클릭 화합물
TW202241886A (zh) 雌激素受體調節劑
EP4596544A1 (en) Ep300/cbp regulator, and preparation method therefor and use thereof
EP4587429B1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
KR20220034038A (ko) Bcl-2 억제제의 나노입자 제형
WO2023049691A1 (en) Cdk7 inhibitors and methods of treating cancer
CN116964049A (zh) 雌激素受体调节剂
US20250312335A1 (en) Flt combination therapy for cancer and compositions therefor
CN115023228A (zh) 组合
TW202126639A (zh) 吡咯啶基系化合物
JP2020529403A (ja) アクリル酸類似体
HK40004087B (en) Estrogen receptor modulators